Motif Neurotech, a Houston-based neurotechnology company, today announced their selection by UK's Advanced Research and Invention Agency (ARIA) for multimillion dollar award to support Motif's ...
MintNeuro has signed a partnership with Motif Neurotech to advance the development of miniature brain-computer interface (BCI) therapy for mental health conditions. The collaboration will bring ...
HOUSTON--(BUSINESS WIRE)--Motif Neurotech, a clinical-stage company developing minimally invasive bioelectronics for mental health, announces the appointment of Steven Goetz as Chief Technology ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Motif Neurotech, one of the ...
Strategic partnership combines MintNeuro's purpose-built neural sensing and stimulation chips with Motif's ultra-miniaturised therapeutic implant platform -- enabling precision neuromodulation and ...
Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has granted Motif Neurotech an investigational device exemption (IDE) to initiate a ...
Neurostimulation has been proven to help relieve symptoms of major depressive disorder—including otherwise difficult-to-treat cases of treatment-resistant depression, or TRD—though currently available ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min In addition to revealing plans ...
The RESONATE early feasibility study will assess safety and viability of the wirelessly-powered XCS System in patients with treatment-resistant depression across eight leading medical institutions.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results